vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -6.6%, a 17.8% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $27.8M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 32.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
ANIP vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $339.5M |
| Net Profit | $27.5M | $-22.6M |
| Gross Margin | — | 11.5% |
| Operating Margin | 14.1% | -2.6% |
| Net Margin | 11.1% | -6.6% |
| Revenue YoY | 29.6% | 48.3% |
| Net Profit YoY | 367.5% | 8.3% |
| EPS (diluted) | $1.14 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $339.5M | ||
| Q3 25 | $227.8M | $354.8M | ||
| Q2 25 | $211.4M | $280.9M | ||
| Q1 25 | $197.1M | $213.8M | ||
| Q4 24 | $190.6M | $229.0M | ||
| Q3 24 | $148.3M | $220.9M | ||
| Q2 24 | $138.0M | $208.4M | ||
| Q1 24 | $137.4M | $192.5M |
| Q4 25 | $27.5M | $-22.6M | ||
| Q3 25 | $26.6M | $-19.1M | ||
| Q2 25 | $8.5M | $-21.6M | ||
| Q1 25 | $15.7M | $-27.2M | ||
| Q4 24 | $-10.3M | $-24.6M | ||
| Q3 24 | $-24.2M | $-14.3M | ||
| Q2 24 | $-2.3M | $-17.8M | ||
| Q1 24 | $18.2M | $-23.7M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 19.4% |
| Q4 25 | 14.1% | -2.6% | ||
| Q3 25 | 15.9% | -2.4% | ||
| Q2 25 | 6.6% | -5.3% | ||
| Q1 25 | 13.3% | -6.1% | ||
| Q4 24 | -2.3% | -4.3% | ||
| Q3 24 | -13.8% | -5.8% | ||
| Q2 24 | 3.7% | -7.9% | ||
| Q1 24 | 14.8% | -5.3% |
| Q4 25 | 11.1% | -6.6% | ||
| Q3 25 | 11.7% | -5.4% | ||
| Q2 25 | 4.0% | -7.7% | ||
| Q1 25 | 8.0% | -12.7% | ||
| Q4 24 | -5.4% | -10.7% | ||
| Q3 24 | -16.3% | -6.5% | ||
| Q2 24 | -1.7% | -8.5% | ||
| Q1 24 | 13.2% | -12.3% |
| Q4 25 | $1.14 | $-0.22 | ||
| Q3 25 | $1.13 | $-0.20 | ||
| Q2 25 | $0.36 | $-0.23 | ||
| Q1 25 | $0.69 | $-0.29 | ||
| Q4 24 | $-0.45 | $-0.26 | ||
| Q3 24 | $-1.27 | $-0.16 | ||
| Q2 24 | $-0.14 | $-0.20 | ||
| Q1 24 | $0.82 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $49.9M |
| Total DebtLower is stronger | — | $444.1M |
| Stockholders' EquityBook value | $540.7M | $-1.9M |
| Total Assets | $1.4B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $49.9M | ||
| Q3 25 | $262.6M | $34.0M | ||
| Q2 25 | $217.8M | $44.0M | ||
| Q1 25 | $149.8M | $33.1M | ||
| Q4 24 | $144.9M | $26.2M | ||
| Q3 24 | $145.0M | $22.4M | ||
| Q2 24 | $240.1M | $24.3M | ||
| Q1 24 | $228.6M | $12.6M |
| Q4 25 | — | $444.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $-1.9M | ||
| Q3 25 | $505.8M | $11.4M | ||
| Q2 25 | $436.8M | $18.2M | ||
| Q1 25 | $418.6M | $71.4M | ||
| Q4 24 | $403.7M | $97.5M | ||
| Q3 24 | $405.9M | $110.3M | ||
| Q2 24 | $455.8M | $81.5M | ||
| Q1 24 | $452.0M | $91.7M |
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $983.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $36.7M |
| Free Cash FlowOCF − Capex | $29.1M | $27.8M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 0.5% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $36.7M | ||
| Q3 25 | $44.1M | $-26.6M | ||
| Q2 25 | $75.8M | $-7.0M | ||
| Q1 25 | $35.0M | $-22.1M | ||
| Q4 24 | $15.9M | $2.8M | ||
| Q3 24 | $12.5M | $-332.0K | ||
| Q2 24 | $17.4M | $-23.7M | ||
| Q1 24 | $18.3M | $8.0M |
| Q4 25 | $29.1M | $27.8M | ||
| Q3 25 | $38.0M | $-44.7M | ||
| Q2 25 | $71.8M | $-27.5M | ||
| Q1 25 | $32.5M | $-63.4M | ||
| Q4 24 | $13.5M | $-15.4M | ||
| Q3 24 | $7.7M | $-36.7M | ||
| Q2 24 | $13.0M | $-59.9M | ||
| Q1 24 | $13.7M | $-60.9M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 16.7% | -12.6% | ||
| Q2 25 | 34.0% | -9.8% | ||
| Q1 25 | 16.5% | -29.7% | ||
| Q4 24 | 7.1% | -6.7% | ||
| Q3 24 | 5.2% | -16.6% | ||
| Q2 24 | 9.4% | -28.7% | ||
| Q1 24 | 10.0% | -31.7% |
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 2.7% | 5.1% | ||
| Q2 25 | 1.9% | 7.3% | ||
| Q1 25 | 1.3% | 19.3% | ||
| Q4 24 | 1.3% | 7.9% | ||
| Q3 24 | 3.2% | 16.5% | ||
| Q2 24 | 3.2% | 17.4% | ||
| Q1 24 | 3.3% | 35.8% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
